Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi‐institutional retrospective study
Background Hepatocellular carcinoma (HCC) ranks third in cancer‐related deaths globally. Despite treatment advances, high post‐hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and p...
Gespeichert in:
| Veröffentlicht in: | Journal of hepato-biliary-pancreatic sciences 2024-11, Vol.31 (11), p.798-808 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 808 |
|---|---|
| container_issue | 11 |
| container_start_page | 798 |
| container_title | Journal of hepato-biliary-pancreatic sciences |
| container_volume | 31 |
| creator | Imaoka, Yuki Ohira, Masahiro Kobayashi, Tsuyoshi Honmyo, Naruhiko Hamaoka, Michinori Onoe, Takashi Takei, Daisuke Oishi, Koichi Abe, Tomoyuki Nakayama, Toshihiro Akabane, Miho Sasaki, Kazunari Ohdan, Hideki |
| description | Background
Hepatocellular carcinoma (HCC) ranks third in cancer‐related deaths globally. Despite treatment advances, high post‐hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and perioperative blood loss, impacting extrahepatic recurrence. Natural killer (NK) cells are crucial in countering circulating tumor cells through TRAIL‐mediated pathways. The aim of this study was to validate the liver immune status index (LISI) as a predictive tool for liver NK cell antitumor efficiency, particularly in HCC patients with vascular invasion.
Methods
A retrospective analysis of 1337 primary HCC hepatectomies was conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Clinicodemographic data were extracted from electronic medical records. Prognostic indices (FIB‐4, ALBI, ALICE, GNRI, APRI, and LISI) were evaluated using area under the receiver operating characteristic curve values. Survival analyses employed Kaplan–Meier estimations and log‐rank tests.
Results
LISI significantly correlated with other prognostic markers and stratified patients into risk groups with distinct overall survival (OS) and RR. It showed superior predictive performance for 2‐year OS and RR, especially in patients with vascular invasion. Over longer periods, APRI and FIB‐4 index reliabilities improved. The HISCO‐HCC score, combining LISI, tumor burden score, and alpha‐fetoprotein levels, enhanced prognostic accuracy.
Conclusion
LISI outperformed existing models, particularly in HCC with vascular invasion. The HISCO‐HCC score offers improved prognostic precision, guiding immunotherapeutic strategies and individualized patient care in HCC.
Imaoka and colleagues demonstrated that the liver immune status index outperformed existing models in predicting postoperative outcomes, particularly in hepatocellular carcinoma with vascular invasion. The HISCO‐HCC score, combining the liver immune status index, tumor burden score, and α‐fetoprotein levels, offers enhanced prognostic accuracy, guiding immunotherapeutic strategies and individualized patient care. |
| doi_str_mv | 10.1002/jhbp.12070 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11589398</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3132707060</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3380-6024cf6a0321fccc6819909ea83381e932d1704d5115e2d75a174ce87937d1b03</originalsourceid><addsrcrecordid>eNp9ks1uEzEQx1cIRKvSCw-ALHFBSCn-SNY2F9RWhYIqwQHOluOdTRx57cUfgdx4BF6GF-JJ8DYlAg744LFmfvPXX-NpmscEnxGM6YvNejmeEYo5vtccE9GKWSsFvX948_lRc5rSBtfDCJMMP2yOaiBMMH7c_Ljaald0tsGj0KMxhpUPKVuDoO-t0WY3pZ3dQkR2GIoHlLLOJSHrO_ha79oDnTXZ-hUaa2sYIVa9LaBQsgkDTChaw6hzMOBccToio6OxPgwa1bQFn9NLdI6G4rL9-e279dVBLpMp7VCEHEMawdyKply63aPmQa9dgtO7eNJ8en318fJ6dvP-zdvL85uZYUzgWYvp3PStxoyS3hjTCiIllqBFLROQjHaE43m3IGQBtOMLTfjcgOCS8Y4sMTtpXu11x7IcoDPVaNROjdEOOu5U0Fb9XfF2rVZhq6qgkEyKqvDsTiGGzwVSVoNN0xi0h1CSYgQL3lJJFxV9-g-6CSXWCUwUo7x-cTtZer6nTB1KitAf3BCspo1Q00ao242o8JM__R_Q3_9fAbIHvlgHu_9IqXfXFx_2or8A3wHHeg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3132707060</pqid></control><display><type>article</type><title>Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi‐institutional retrospective study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Imaoka, Yuki ; Ohira, Masahiro ; Kobayashi, Tsuyoshi ; Honmyo, Naruhiko ; Hamaoka, Michinori ; Onoe, Takashi ; Takei, Daisuke ; Oishi, Koichi ; Abe, Tomoyuki ; Nakayama, Toshihiro ; Akabane, Miho ; Sasaki, Kazunari ; Ohdan, Hideki</creator><creatorcontrib>Imaoka, Yuki ; Ohira, Masahiro ; Kobayashi, Tsuyoshi ; Honmyo, Naruhiko ; Hamaoka, Michinori ; Onoe, Takashi ; Takei, Daisuke ; Oishi, Koichi ; Abe, Tomoyuki ; Nakayama, Toshihiro ; Akabane, Miho ; Sasaki, Kazunari ; Ohdan, Hideki ; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO) ; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)</creatorcontrib><description>Background
Hepatocellular carcinoma (HCC) ranks third in cancer‐related deaths globally. Despite treatment advances, high post‐hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and perioperative blood loss, impacting extrahepatic recurrence. Natural killer (NK) cells are crucial in countering circulating tumor cells through TRAIL‐mediated pathways. The aim of this study was to validate the liver immune status index (LISI) as a predictive tool for liver NK cell antitumor efficiency, particularly in HCC patients with vascular invasion.
Methods
A retrospective analysis of 1337 primary HCC hepatectomies was conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Clinicodemographic data were extracted from electronic medical records. Prognostic indices (FIB‐4, ALBI, ALICE, GNRI, APRI, and LISI) were evaluated using area under the receiver operating characteristic curve values. Survival analyses employed Kaplan–Meier estimations and log‐rank tests.
Results
LISI significantly correlated with other prognostic markers and stratified patients into risk groups with distinct overall survival (OS) and RR. It showed superior predictive performance for 2‐year OS and RR, especially in patients with vascular invasion. Over longer periods, APRI and FIB‐4 index reliabilities improved. The HISCO‐HCC score, combining LISI, tumor burden score, and alpha‐fetoprotein levels, enhanced prognostic accuracy.
Conclusion
LISI outperformed existing models, particularly in HCC with vascular invasion. The HISCO‐HCC score offers improved prognostic precision, guiding immunotherapeutic strategies and individualized patient care in HCC.
Imaoka and colleagues demonstrated that the liver immune status index outperformed existing models in predicting postoperative outcomes, particularly in hepatocellular carcinoma with vascular invasion. The HISCO‐HCC score, combining the liver immune status index, tumor burden score, and α‐fetoprotein levels, offers enhanced prognostic accuracy, guiding immunotherapeutic strategies and individualized patient care.</description><identifier>ISSN: 1868-6974</identifier><identifier>ISSN: 1868-6982</identifier><identifier>EISSN: 1868-6982</identifier><identifier>DOI: 10.1002/jhbp.12070</identifier><identifier>PMID: 39313837</identifier><language>eng</language><publisher>Japan: Wiley Subscription Services, Inc</publisher><subject>Aged ; antitumor activity ; Carcinoma, Hepatocellular - immunology ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; Female ; Hepatectomy ; hepatocellular carcinoma ; Humans ; Liver cancer ; Liver Neoplasms - immunology ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Male ; Medical prognosis ; Middle Aged ; natural killer cells ; Neoplasm Recurrence, Local - immunology ; Original ; ORIGINAL ARTICLE ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Risk Assessment</subject><ispartof>Journal of hepato-biliary-pancreatic sciences, 2024-11, Vol.31 (11), p.798-808</ispartof><rights>2024 The Author(s). published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato‐Biliary‐Pancreatic Surgery.</rights><rights>2024 The Author(s). Journal of Hepato‐Biliary‐Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato‐Biliary‐Pancreatic Surgery.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3380-6024cf6a0321fccc6819909ea83381e932d1704d5115e2d75a174ce87937d1b03</cites><orcidid>0000-0001-6859-7614 ; 0000-0001-7364-1798 ; 0000-0001-7804-8790 ; 0000-0002-5433-5303 ; 0000-0003-0882-5341 ; 0000-0003-2514-5778</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjhbp.12070$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjhbp.12070$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39313837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Imaoka, Yuki</creatorcontrib><creatorcontrib>Ohira, Masahiro</creatorcontrib><creatorcontrib>Kobayashi, Tsuyoshi</creatorcontrib><creatorcontrib>Honmyo, Naruhiko</creatorcontrib><creatorcontrib>Hamaoka, Michinori</creatorcontrib><creatorcontrib>Onoe, Takashi</creatorcontrib><creatorcontrib>Takei, Daisuke</creatorcontrib><creatorcontrib>Oishi, Koichi</creatorcontrib><creatorcontrib>Abe, Tomoyuki</creatorcontrib><creatorcontrib>Nakayama, Toshihiro</creatorcontrib><creatorcontrib>Akabane, Miho</creatorcontrib><creatorcontrib>Sasaki, Kazunari</creatorcontrib><creatorcontrib>Ohdan, Hideki</creatorcontrib><creatorcontrib>Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)</creatorcontrib><creatorcontrib>Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)</creatorcontrib><title>Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi‐institutional retrospective study</title><title>Journal of hepato-biliary-pancreatic sciences</title><addtitle>J Hepatobiliary Pancreat Sci</addtitle><description>Background
Hepatocellular carcinoma (HCC) ranks third in cancer‐related deaths globally. Despite treatment advances, high post‐hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and perioperative blood loss, impacting extrahepatic recurrence. Natural killer (NK) cells are crucial in countering circulating tumor cells through TRAIL‐mediated pathways. The aim of this study was to validate the liver immune status index (LISI) as a predictive tool for liver NK cell antitumor efficiency, particularly in HCC patients with vascular invasion.
Methods
A retrospective analysis of 1337 primary HCC hepatectomies was conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Clinicodemographic data were extracted from electronic medical records. Prognostic indices (FIB‐4, ALBI, ALICE, GNRI, APRI, and LISI) were evaluated using area under the receiver operating characteristic curve values. Survival analyses employed Kaplan–Meier estimations and log‐rank tests.
Results
LISI significantly correlated with other prognostic markers and stratified patients into risk groups with distinct overall survival (OS) and RR. It showed superior predictive performance for 2‐year OS and RR, especially in patients with vascular invasion. Over longer periods, APRI and FIB‐4 index reliabilities improved. The HISCO‐HCC score, combining LISI, tumor burden score, and alpha‐fetoprotein levels, enhanced prognostic accuracy.
Conclusion
LISI outperformed existing models, particularly in HCC with vascular invasion. The HISCO‐HCC score offers improved prognostic precision, guiding immunotherapeutic strategies and individualized patient care in HCC.
Imaoka and colleagues demonstrated that the liver immune status index outperformed existing models in predicting postoperative outcomes, particularly in hepatocellular carcinoma with vascular invasion. The HISCO‐HCC score, combining the liver immune status index, tumor burden score, and α‐fetoprotein levels, offers enhanced prognostic accuracy, guiding immunotherapeutic strategies and individualized patient care.</description><subject>Aged</subject><subject>antitumor activity</subject><subject>Carcinoma, Hepatocellular - immunology</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Female</subject><subject>Hepatectomy</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - immunology</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>natural killer cells</subject><subject>Neoplasm Recurrence, Local - immunology</subject><subject>Original</subject><subject>ORIGINAL ARTICLE</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><issn>1868-6974</issn><issn>1868-6982</issn><issn>1868-6982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp9ks1uEzEQx1cIRKvSCw-ALHFBSCn-SNY2F9RWhYIqwQHOluOdTRx57cUfgdx4BF6GF-JJ8DYlAg744LFmfvPXX-NpmscEnxGM6YvNejmeEYo5vtccE9GKWSsFvX948_lRc5rSBtfDCJMMP2yOaiBMMH7c_Ljaald0tsGj0KMxhpUPKVuDoO-t0WY3pZ3dQkR2GIoHlLLOJSHrO_ha79oDnTXZ-hUaa2sYIVa9LaBQsgkDTChaw6hzMOBccToio6OxPgwa1bQFn9NLdI6G4rL9-e279dVBLpMp7VCEHEMawdyKply63aPmQa9dgtO7eNJ8en318fJ6dvP-zdvL85uZYUzgWYvp3PStxoyS3hjTCiIllqBFLROQjHaE43m3IGQBtOMLTfjcgOCS8Y4sMTtpXu11x7IcoDPVaNROjdEOOu5U0Fb9XfF2rVZhq6qgkEyKqvDsTiGGzwVSVoNN0xi0h1CSYgQL3lJJFxV9-g-6CSXWCUwUo7x-cTtZer6nTB1KitAf3BCspo1Q00ao242o8JM__R_Q3_9fAbIHvlgHu_9IqXfXFx_2or8A3wHHeg</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Imaoka, Yuki</creator><creator>Ohira, Masahiro</creator><creator>Kobayashi, Tsuyoshi</creator><creator>Honmyo, Naruhiko</creator><creator>Hamaoka, Michinori</creator><creator>Onoe, Takashi</creator><creator>Takei, Daisuke</creator><creator>Oishi, Koichi</creator><creator>Abe, Tomoyuki</creator><creator>Nakayama, Toshihiro</creator><creator>Akabane, Miho</creator><creator>Sasaki, Kazunari</creator><creator>Ohdan, Hideki</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6859-7614</orcidid><orcidid>https://orcid.org/0000-0001-7364-1798</orcidid><orcidid>https://orcid.org/0000-0001-7804-8790</orcidid><orcidid>https://orcid.org/0000-0002-5433-5303</orcidid><orcidid>https://orcid.org/0000-0003-0882-5341</orcidid><orcidid>https://orcid.org/0000-0003-2514-5778</orcidid></search><sort><creationdate>202411</creationdate><title>Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi‐institutional retrospective study</title><author>Imaoka, Yuki ; Ohira, Masahiro ; Kobayashi, Tsuyoshi ; Honmyo, Naruhiko ; Hamaoka, Michinori ; Onoe, Takashi ; Takei, Daisuke ; Oishi, Koichi ; Abe, Tomoyuki ; Nakayama, Toshihiro ; Akabane, Miho ; Sasaki, Kazunari ; Ohdan, Hideki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3380-6024cf6a0321fccc6819909ea83381e932d1704d5115e2d75a174ce87937d1b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>antitumor activity</topic><topic>Carcinoma, Hepatocellular - immunology</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Female</topic><topic>Hepatectomy</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - immunology</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>natural killer cells</topic><topic>Neoplasm Recurrence, Local - immunology</topic><topic>Original</topic><topic>ORIGINAL ARTICLE</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imaoka, Yuki</creatorcontrib><creatorcontrib>Ohira, Masahiro</creatorcontrib><creatorcontrib>Kobayashi, Tsuyoshi</creatorcontrib><creatorcontrib>Honmyo, Naruhiko</creatorcontrib><creatorcontrib>Hamaoka, Michinori</creatorcontrib><creatorcontrib>Onoe, Takashi</creatorcontrib><creatorcontrib>Takei, Daisuke</creatorcontrib><creatorcontrib>Oishi, Koichi</creatorcontrib><creatorcontrib>Abe, Tomoyuki</creatorcontrib><creatorcontrib>Nakayama, Toshihiro</creatorcontrib><creatorcontrib>Akabane, Miho</creatorcontrib><creatorcontrib>Sasaki, Kazunari</creatorcontrib><creatorcontrib>Ohdan, Hideki</creatorcontrib><creatorcontrib>Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)</creatorcontrib><creatorcontrib>Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of hepato-biliary-pancreatic sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imaoka, Yuki</au><au>Ohira, Masahiro</au><au>Kobayashi, Tsuyoshi</au><au>Honmyo, Naruhiko</au><au>Hamaoka, Michinori</au><au>Onoe, Takashi</au><au>Takei, Daisuke</au><au>Oishi, Koichi</au><au>Abe, Tomoyuki</au><au>Nakayama, Toshihiro</au><au>Akabane, Miho</au><au>Sasaki, Kazunari</au><au>Ohdan, Hideki</au><aucorp>Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)</aucorp><aucorp>Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi‐institutional retrospective study</atitle><jtitle>Journal of hepato-biliary-pancreatic sciences</jtitle><addtitle>J Hepatobiliary Pancreat Sci</addtitle><date>2024-11</date><risdate>2024</risdate><volume>31</volume><issue>11</issue><spage>798</spage><epage>808</epage><pages>798-808</pages><issn>1868-6974</issn><issn>1868-6982</issn><eissn>1868-6982</eissn><abstract>Background
Hepatocellular carcinoma (HCC) ranks third in cancer‐related deaths globally. Despite treatment advances, high post‐hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and perioperative blood loss, impacting extrahepatic recurrence. Natural killer (NK) cells are crucial in countering circulating tumor cells through TRAIL‐mediated pathways. The aim of this study was to validate the liver immune status index (LISI) as a predictive tool for liver NK cell antitumor efficiency, particularly in HCC patients with vascular invasion.
Methods
A retrospective analysis of 1337 primary HCC hepatectomies was conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Clinicodemographic data were extracted from electronic medical records. Prognostic indices (FIB‐4, ALBI, ALICE, GNRI, APRI, and LISI) were evaluated using area under the receiver operating characteristic curve values. Survival analyses employed Kaplan–Meier estimations and log‐rank tests.
Results
LISI significantly correlated with other prognostic markers and stratified patients into risk groups with distinct overall survival (OS) and RR. It showed superior predictive performance for 2‐year OS and RR, especially in patients with vascular invasion. Over longer periods, APRI and FIB‐4 index reliabilities improved. The HISCO‐HCC score, combining LISI, tumor burden score, and alpha‐fetoprotein levels, enhanced prognostic accuracy.
Conclusion
LISI outperformed existing models, particularly in HCC with vascular invasion. The HISCO‐HCC score offers improved prognostic precision, guiding immunotherapeutic strategies and individualized patient care in HCC.
Imaoka and colleagues demonstrated that the liver immune status index outperformed existing models in predicting postoperative outcomes, particularly in hepatocellular carcinoma with vascular invasion. The HISCO‐HCC score, combining the liver immune status index, tumor burden score, and α‐fetoprotein levels, offers enhanced prognostic accuracy, guiding immunotherapeutic strategies and individualized patient care.</abstract><cop>Japan</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39313837</pmid><doi>10.1002/jhbp.12070</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6859-7614</orcidid><orcidid>https://orcid.org/0000-0001-7364-1798</orcidid><orcidid>https://orcid.org/0000-0001-7804-8790</orcidid><orcidid>https://orcid.org/0000-0002-5433-5303</orcidid><orcidid>https://orcid.org/0000-0003-0882-5341</orcidid><orcidid>https://orcid.org/0000-0003-2514-5778</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1868-6974 |
| ispartof | Journal of hepato-biliary-pancreatic sciences, 2024-11, Vol.31 (11), p.798-808 |
| issn | 1868-6974 1868-6982 1868-6982 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11589398 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Aged antitumor activity Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Female Hepatectomy hepatocellular carcinoma Humans Liver cancer Liver Neoplasms - immunology Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - surgery Male Medical prognosis Middle Aged natural killer cells Neoplasm Recurrence, Local - immunology Original ORIGINAL ARTICLE Predictive Value of Tests Prognosis Retrospective Studies Risk Assessment |
| title | Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi‐institutional retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T11%3A23%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20prognostic%20efficacy%20of%20liver%20immune%20status%20index%20in%20predicting%20postoperative%20outcomes%20in%20hepatocellular%20carcinoma%20patients:%20A%20multi%E2%80%90institutional%20retrospective%20study&rft.jtitle=Journal%20of%20hepato-biliary-pancreatic%20sciences&rft.au=Imaoka,%20Yuki&rft.aucorp=Hiroshima%20Surgical%20Study%20Group%20of%20Clinical%20Oncology%20(HiSCO)&rft.date=2024-11&rft.volume=31&rft.issue=11&rft.spage=798&rft.epage=808&rft.pages=798-808&rft.issn=1868-6974&rft.eissn=1868-6982&rft_id=info:doi/10.1002/jhbp.12070&rft_dat=%3Cproquest_pubme%3E3132707060%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3132707060&rft_id=info:pmid/39313837&rfr_iscdi=true |